The research activities, particularly protein research, in several therapeutic areas are rising in order to address the unmet medical requirements. Before, the development of proteins and monoclonal antibodies as therapeutic agents was avoided by pharmaceutical companies because of their low stability, size, rate of degradation, and poor delivery. However, now monoclonal antibodies and proteins are being developed for catering to the unmet needs in different therapeutic areas, such as oncology, infectious diseases, metabolic diseases, and cardiovascular diseases. This has resulted in increased attention on making use of proteins which mimic the function of mediators involved in different pathologic processes. Attributed to this, the demand for protein A resin is rising.
Protein A resin is an affinity chromatography resin which is utilized as a separation medium during purification techniques of immunoprecipitation and chromatography. As per a P&S Intelligence report in 2019, the global protein A resin market size reached a value of $486.4 million and is expected to generate a revenue of $1,020.7 million by 2030, advancing at a 7.0% CAGR during the forecast period (2019–2030). Two end users of protein A resin are academic institutes & research laboratories and biotechnology & pharmaceutical industries. Out of these, biotechnology & pharmaceutical industries are projected to make the most use of protein A resin during the forecast period.
The two major applications of protein A resin are immunoprecipitation and antibody purification. Between these two, the larger demand for protein A resin was created for the antibody purification application during 2014–2019, and the resin is further predicted to be the more in demand for this application during the forecast period. This is because of the high production and rising demand for antibodies primarily monoclonal antibody for therapeutic application. Geographically, North America is expected to create the largest demand for protein A resin during the forecast period, owing to the presence of large-scale manufacturers of drugs.
A major driving factor of the protein A resin market is the growing burden of chronic diseases. For example, as per the International Agency for Research on Cancer, a specialized cancer agency of the World Health Organization, 12.7 million new patients were diagnosed with cancer in 2008 and the number is predicted to reach 21.4 million by 2030. Monoclonal antibodies hold multiple properties as therapeutics, including suitable pharmacokinetic profiles, low toxicity and immunogenicity, and customizable solubility features. Due to this, pharmaceutical and biotechnology companies are focusing on developing novel therapeutics for the treatment of these diseases.
Read more: https://www.psmarketresearch.com/market-analysis/protein-a-resin-market
 |
| To Learn more About this report@ https://bit.ly/2wBq0My |
Protein A resin is an affinity chromatography resin which is utilized as a separation medium during purification techniques of immunoprecipitation and chromatography. As per a P&S Intelligence report in 2019, the global protein A resin market size reached a value of $486.4 million and is expected to generate a revenue of $1,020.7 million by 2030, advancing at a 7.0% CAGR during the forecast period (2019–2030). Two end users of protein A resin are academic institutes & research laboratories and biotechnology & pharmaceutical industries. Out of these, biotechnology & pharmaceutical industries are projected to make the most use of protein A resin during the forecast period.
The two major applications of protein A resin are immunoprecipitation and antibody purification. Between these two, the larger demand for protein A resin was created for the antibody purification application during 2014–2019, and the resin is further predicted to be the more in demand for this application during the forecast period. This is because of the high production and rising demand for antibodies primarily monoclonal antibody for therapeutic application. Geographically, North America is expected to create the largest demand for protein A resin during the forecast period, owing to the presence of large-scale manufacturers of drugs.
A major driving factor of the protein A resin market is the growing burden of chronic diseases. For example, as per the International Agency for Research on Cancer, a specialized cancer agency of the World Health Organization, 12.7 million new patients were diagnosed with cancer in 2008 and the number is predicted to reach 21.4 million by 2030. Monoclonal antibodies hold multiple properties as therapeutics, including suitable pharmacokinetic profiles, low toxicity and immunogenicity, and customizable solubility features. Due to this, pharmaceutical and biotechnology companies are focusing on developing novel therapeutics for the treatment of these diseases.
Read more: https://www.psmarketresearch.com/market-analysis/protein-a-resin-market
